Trends in antibiotic resistance of staphylococci over an eight-year period: Differences in the emergence of resistance between coagulase positive and coagulase-negative staphylococci

Microbial Drug Resistance

Volumn 4, Issue 2, 1998, Pages 119-122

  Laverdiere M ^a   Weiss, K ^a   Rivest, R ^a   Delorme, J ^a  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFALOTIN; CEFOXITIN; CEFTAZIDIME; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; FUSIDIC ACID; NITROFURANTOIN; NORFLOXACIN; OXACILLIN; PENICILLIN G; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; COAGULASE NEGATIVE STAPHYLOCOCCUS; COAGULASE POSITIVE STAPHYLOCOCCUS; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE;

BACTERIA (MICROORGANISMS); STAPHYLOCOCCI; STAPHYLOCOCCUS AUREUS;

EID: 0031749324     PISSN: 10766294     EISSN: None     Source Type: Journal    
DOI: 10.1089/mdr.1998.4.119     Document Type: Article

References (14)

1. Conly, J.M., S.D. Shafran. 1995. Confronting antibiotic-resistant organisms: A Canadian perspective. Can. J. Infect. Dis. 6:130-132.
2. Farber M., and V.T. Rosdahl. 1990. Susceptibility to fucidic acid among Danish Staphylococcus aureus and fucidic acid consumption. J. Antimicrob. Chemo. 25 (suppl B): 7-14.
3. Forward, K., P. Franks, D.L. Low, M. Laverdiere, et al. 1998. A cross Canada survey of resistance to piperacillin-tazobactam and other antibiotics against 2747 aerobic blood culture isolates. Can. J. Infect. Dis. 9:33-44.
4. Hoiby, N., J.O. Jarley, M. Kemp, et al. 1997. Excretion of ciprofloxacin in sweat and multiresistant Staphylococcus epidermidis. Lancet 349:167-169.
5. Kernodle, D.S., N.L. Barg, and A.B. Kaiser. 1988. Low-level colonization of hospitalized patients with methicillin-resistant coagulase-negative staphylococci and emergence of the organisms during surgical antimicrobial prophylaxis. Antimicrob. Agents Chemother. 32:202-208.
6. Kloss, W.E., and T.L. Bannerman. 1995. Staphylococci and Micrococcus, pp. 282-298. In Murray, P.R., M.J. Baron, M.A. Pfaller et al. (eds.), Manual of Clinical Microbiology ASM Press, Washington.
7. Laverdière, M. 1992. Canadians monitor resistance of S. aureus to fucidic acid. Can. J. Derm. 2:205.
8. National Committee for Clinical Laboratory Standard. 1988. Methods for Dilution Antimicrobial Susceptibility That Grow Aerobically, 2nd ed. Tentative Standard. National Committee for Clinical Laboratory Standard, Villanova, PA.
9. National Committee for Clinical Laboratory Standard. 1990. Methods for Dilution Antimicrobial Susceptibility That Grow Aerobically, 2nd ed. Approved Standard. National Committee for Clinical Laboratory Standard, Villanova, PA.
10. National Committee for Clinical Laboratory Standard. 1993. Methods for Dilution Antimicrobial Susceptibility That Grow Aerobically, 3rd ed. Approved Standard. National Committee for Clinical Laboratory Standard, Villanova, PA.
11. Pittet, D., and R.P. Wenzel 1995. Nosocomial bloodstream infections. Arch. Intern. Med. 155:1177-1184.
12. Steinberg, J.P., C.C. Clark, and B.O. Hackman. 1996. Nosocomial and community-acquired Staphylococcus aureus bacteriemias from 1980 to 1993: Impact of intravascular devices and methicillin resistance. Clin. Infect. Dis. 23:255-259.
13. Thornsberry, C. 1988. The development of antimicrobial resistance in staphylococci. J. Antimicrob. Chemoth. 21 (suppl C): 9-16.
14. Toma, E., and D. Barriault. 1995. Antimicrobial activity of fusidic acid and disk diffusion susceptibility testing criteria for gram-positive cocci. Antimicrob. Agents Chemother. 33:1712-1715.